Although most patients with hyperadrenergic POTS do not have this genome mutation, epigenetic modification at this gene locus which decreases expression of the NET protein has also been associated with POTS patients. This evidence concerns the gene SLC6A2 and postural orthostatic tachycardia syndrome.